Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.62 |
| ▸ | RAD52 | P43351 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168008 | 0.97 | FPR2 (0.61) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10168440 | 0.92 | FPR2 (0.68) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4284895 | 0.90 | FPR2 (0.64) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10168902 | 0.89 | KIF11 (0.70) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4281060 | 0.89 | FPR2 (0.68) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL13693101 | 0.88 | HRH1 (0.53) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10168006 | 0.88 | FPR2 (0.62) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10168005 | 0.88 | FPR2 (0.64) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4274255 | 0.87 | FPR2 (0.61) | FPR2RAD52LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4279887 | 0.83 | FPR2 (0.84) | FPR2RAD52LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IMMUNE CONTROL, INC. | 2010-05-27 | — | — | US | disclosed |
| WO-2010056979-A1 | PHENOTHIAZINE DERIVATIVES FOR TREATMENT OF ASTHMA | IMMUNE CONTROL, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | IMMUNE CONTROL, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2010009332-A1 | BINDING AND INHIBITING 5-HT4 RECEPTOR | IMMUNE CONTROL, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | IMMUNE CONTROL, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130457-A1 | Phenothiazine Derivatives for Treatment of Asthma | IL5, HRH4, TLR5 | FPR2 80/4885RAD52 3707/4885LMNA 3774/4885 |
| US-20100035858-A1 | Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor | HTR4, HTR3B, HTR5A | FPR2 70/4885RAD52 3034/4885LMNA 4056/4885 |
| US-20090275557-A1 | Novel Composition for Treatment of Diseases Related to Activated Lymphocytes | TPH1, HTR5A, HTR6 | FPR2 43/4885RAD52 3118/4885LMNA 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.